Article
Biochemistry & Molecular Biology
Sarina Cameron, Genevieve Deblois, James R. Hawley, Aditi Qamra, Stanley Zhou, Seyed Ali Madani Tonekaboni, Alexander Murison, Romy Van Vliet, Juan Liu, Jason W. Locasale, Mathieu Lupien
Summary: Predicting and treating recurrence in intermediate-risk prostate cancer patients is challenging. This study found that chronic hypoxia leads to an androgen-independent state in prostate cancer cells, promoting cancer progression. These findings may provide additional strategies for treating hypoxic prostate cancer.
Review
Oncology
Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, Christelle Fargette, Michael Baboudjian, Laurence Colleaux, David Taieb, Palma Rocchi
Summary: Castration-resistant prostate cancer remains a significant medical challenge, and it is important to understand the underlying mechanisms of resistance and develop new treatment approaches. This review provides an overview of the mechanisms contributing to CRPC progression and discusses current treatment options.
Review
Andrology
Koji Hatano, Norio Nonomura
Summary: The introduction of novel therapeutic agents has expanded the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). However, cross-resistance between treatments may occur, and the optimal treatment sequence must be considered.
WORLD JOURNAL OF MENS HEALTH
(2022)
Review
Pharmacology & Pharmacy
Maoping Cai, Xian-Lu Song, Xin-An Li, Mingkun Chen, Jiading Guo, Dong Hua Yang, Zhanghui Chen, Shan-Chao Zhao
Summary: Castration-resistant prostate cancer (CRPC), especially metastatic CRPC (mCRPC), is a common and deadly malignancy in men worldwide. The natural or acquired drug resistance of CRPC makes clinical treatment challenging. Understanding the mechanisms of drug resistance in mCRPC is essential for developing effective therapeutic strategies. This review focuses on new insights in mCRPC treatment and discusses the mechanisms governing resistance to new drugs, such as taxanes, androgen receptor signaling inhibitors (ARSIs), and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Strategies to overcome drug resistance based on these mechanisms are also discussed.
DRUG RESISTANCE UPDATES
(2023)
Review
Oncology
Otasowie Odiase, Lindsay Noah-Vermillion, Brittany A. Simone, Paul D. Aridgides
Summary: FDA approved anti-VEGF therapy for melanoma in 2011, followed by immunotherapy for CTLA-4 and PD-1 in 2012. Targeted therapies have shown efficacy in solid tumors and are being incorporated into upfront management. In cervical cancer treatment, integrating targeted therapies with traditional CRT is a promising approach for improving outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Maria Massaro, Giuseppe Facondo, Gianluca Vullo, Anna Maria Aschelter, Alessandro Rossi, Vitaliana De Sanctis, Paolo Marchetti, Mattia Falchetto Osti, Maurizio Valeriani
Summary: This study aimed to investigate the efficacy of radiotherapy as metastasis-directed therapy in metastatic castration-resistant prostate cancer patients, and found that radiotherapy has a positive impact on prolonging the clinical benefit of ARTT.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Frantzeska Giginis, Joshua Wang, Aaron Chavez, Manuela Martins-Green
Summary: Prostate Cancer (PCa) is the second most prevalent cancer in the world. Currently, most treatments for PCa involve Androgen Deprivation Therapy (ADT) which is not effective for metastatic Castration-Resistant Prostate Cancer (mCRPC). Decreasing the enzyme catalase, which reduces oxidative stress levels, has the potential to provide another target for Prostate Cancer therapy.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Ramesh Singh, Huan Meng, Tao Shen, Lance Edward V. Lumahan, Steven Nguyen, Hong Shen, Subhamoy Dasgupta, Li Qin, Dileep Karri, Bokai Zhu, Feng Yang, Cristian Coarfa, Bert W. O'Malley, Ping Yi
Summary: Castration-resistant prostate cancer (CRPC) is a major clinical challenge, and the androgen receptor (AR) is a critical oncogenic player. This study identifies TRAF4 as a key mediator of AR-regulated transcriptional reprogramming in CRPC, promoting its development.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Oncology
Rafael S. Martinez, Mark J. Salji, Linda Rushworth, Chara Ntala, Giovanny Rodriguez Blanco, Ann Hedley, William Clark, Paul Peixoto, Eric Hervouet, Elodie Renaude, Sonia H. Y. Kung, Laura C. A. Galbraith, Colin Nixon, Sergio Lilla, Gillian M. Mackay, Ladan Fazli, Luke Gaughan, David Sumpton, Martin E. Gleave, Sara Zanivan, Arnaud Blomme, Hing Y. Leung
Summary: This study identified SLFN5 as a novel regulator of the LAT1 amino acid transporter in castration-resistant prostate cancer (CRPC), contributing to mTORC1 activity. High expression of SLFN5 in CRPC tumors was correlated with poor patient outcome, indicating its clinical relevance as a potential target for CRPC treatment.
Article
Medicine, Research & Experimental
Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, Joung Eun Lim, Hye-Jeong Kim, Ghee Young Kwon, Joshua A. Jackman, Jeong Hoon Kim
Summary: The study identified BCT as a potent inhibitor targeting both AR-FL and AR-V7 activities in CRPC, effectively suppressing tumor growth and metastasis. Mechanistically, BCT disrupts the interaction of HSP90 with AR-FL/AR-V7, leading to their degradation and showing promising therapeutic potential against CRPC.
Article
Biochemistry & Molecular Biology
Arielle Shkedi, Isabelle R. Taylor, Frank Echtenkamp, Poornima Ramkumar, Mohamed Alshalalfa, Genesis M. Rivera-Marquez, Michael A. Moses, Hao Shao, Robert Jeffrey Karnes, Len Neckers, Felix Feng, Martin Kampmann, Jason E. Gestwicki
Summary: Castration-resistant prostate cancer (CRPC) is associated with increased reliance on heat shock protein 70 (HSP70) and mitochondrial chaperone protein, HSP60, is selectively required in CRPC cell lines. Knockdown of HSP60 results in loss of mitochondrial spare respiratory capacity and poor survival in prostate cancer patients.
CELL CHEMICAL BIOLOGY
(2022)
Article
Urology & Nephrology
Edmond M. Kwan, Heidi Fettke, Maria M. Docanto, Sarah Q. To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, Lisa-Jane K. Graham, Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D. Davis, Phillip Parente, Carmel Pezaro, Tilman Todenhoefer, Lisa G. Horvath, Arun A. Azad
Summary: The study aimed to develop a prognostic whole-blood gene signature for mCRPC patients by analyzing gene expression in patient samples. The results showed that the gene signature based on certain genes associated with the androgen receptor had strong prognostic utility in predicting survival outcomes for patients starting contemporary systemic therapies.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Cell Biology
Mayao Luo, Yifan Zhang, Zhuofan Xu, Chenwei Wu, Yuedian Ye, Rui Liu, Shidong Lv, Qiang Wei
Summary: The combination therapy of tautomycin and enzalutamide could achieve a more comprehensive inhibition of androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC). Enzalutamide enhanced tautomycin-induced AR degradation by competing with residual androgens, while tautomycin decreased ARv7 levels through AR degradation. This combination therapy may represent a new therapeutic strategy for CRPC.
CELL DEATH DISCOVERY
(2022)
Article
Biochemistry & Molecular Biology
Levi Groen, Iris Kloots, David Englert, Kelly Seto, Lana Estafanos, Paul Smith, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken
Summary: The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is well recognized. The earliest methods for enriching CTCs relied on antibody-based positive selection, but it has limitations in capturing the heterogeneity of cancer. This study used the recently FDA-approved Parsortix (R) technology to enrich CTCs from prostate cancer patients and found that targeted CTC transcriptome profiling may be predictive of therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Hao Han, Hui Li, Yifan Ma, Zhite Zhao, Qingling An, Jumei Zhao, Changhong Shi
Summary: Monoamine oxidase A (MAOA) is an enzyme that plays a crucial role in prostate cancer progression, including various stages such as castration-resistant prostate cancer and metastasis. It is also involved in intercellular interactions between prostate cancer cells and the tumor microenvironment. Targeting MAOA can disrupt these interactions and potentially improve the efficacy of prostate cancer therapy. Furthermore, MAOA targeting can enhance the sensitivity of enzalutamide, block the growth of prostate cancer cells, and potentially improve immune checkpoint inhibition. Overall, MAOA is a promising therapeutic target that requires further investigation in both preclinical and clinical settings.
Article
Hematology
Anna K. Brandtner, Georg F. Lehner, Andreas Pircher, Clemens Feistritzer, Michael Joannidis
Summary: In this study, it was found that inflammation can induce endothelial cells to express tissue factor and trigger a procoagulant state, with the highest TF-PCA observed in microvascular endothelial cells. The correlation between IL-6 and TF levels was positive in a cohort of septic patients. The ratio of TF to its inhibitor TFPI on the endothelial membrane differs between endothelial cell subtypes, possibly explaining the susceptibility of the microvascular system to inflammation-induced thrombosis.
THROMBOSIS RESEARCH
(2021)
Article
Oncology
Laurenz Nagl, Andreas Seeber, Gerlig Widmann, Katja Schmitz, Herbert Maier, Georg Pall, Dominik Wolf, Andreas Pircher
Summary: Primary pulmonary sarcomas are rare mesenchymal lung cancers that require histological analysis and detailed staging examinations for definitive diagnosis. Surgery is the mainstay of therapy, with prognosis influenced by tumor size, lymph node status, and histological grading. Multimodal therapy approaches like (neo)adjuvant chemo- and radiotherapy may improve local tumor control.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Jan-Paul Bohn, Sabrina Neururer, Markus Pirklbauer, Andreas Pircher, Dominik Wolf
Summary: This study retrospectively analyzed the long-term clinical outcomes of 83 consecutive HCL patients and found that HCL patients can expect a normal lifespan when treated with purine analogues, regardless of their pretreatment history, age at diagnosis, or treatment time.
Article
Biochemistry & Molecular Biology
Isabel Heidegger, Georgios Fotakis, Anne Offermann, Jermaine Goveia, Sophia Daum, Stefan Salcher, Asma Noureen, Hetty Timmer-Bosscha, Georg Schaefer, Annemiek Walenkamp, Sven Perner, Aleksandar Beatovic, Matthieu Moisse, Christina Plattner, Anne Krogsdam, Johannes Haybaeck, Sieghart Sopper, Stefanie Thaler, Markus A. Keller, Helmut Klocker, Zlatko Trajanoski, Dominik Wolf, Andreas Pircher
Summary: This study provides a comprehensive analysis of prostate cancer tumor endothelial cells (TEC) and identifies potential therapeutic targets, specifically the CXCL12/CXCR4 interaction, to interfere with tumor angiogenesis in prostate cancer. Understanding the cell-to-cell communication networks in the tumor microenvironment contributes to the development of new therapeutic approaches for prostate cancer.
Editorial Material
Oncology
Isabel Heidegger, Andreas Pircher
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
(2022)
Editorial Material
Oncology
Andreas Pircher, Roberto N. Miranda
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Florian Kocher, Alberto Puccini, Gerold Untergasser, Agnieszka Martowicz, Kai Zimmer, Andreas Pircher, Yasmine Baca, Joanne Xiu, Johannes Haybaeck, Piotr Tymoszuk, Richard M. Goldberg, Angelica Petrillo, Anthony F. Shields, Mohamed E. Salem, John L. Marshall, Michael Hall, W. Michael Korn, Chadi Nabhan, Francesca Battaglin, Heinz-Josef Lenz, Emil Lou, Su-Pin Choo, Chee-Keong Toh, Silvia Gasteiger, Renate Pichler, Dominik Wolf, Andreas Seeber
Summary: This study reveals that high intratumoral CXCR4 mRNA expression in pancreatic ductal adenocarcinoma (PDAC) is associated with a tumor microenvironment rich in T cells and macrophages, as well as elevated expression of inhibitory immune checkpoints. These findings suggest that CXCR4 could serve as a potential predictive biomarker for PDAC patients undergoing immune checkpoint inhibition.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Maximilian Boesch, Lena Horvath, Florent Baty, Andreas Pircher, Dominik Wolf, Stephan Spahn, Ravid Straussman, Herbert Tilg, Martin H. Brutsche
Summary: This article reviews the latest research on the tumor-associated microbiome, highlighting its impact on anticancer immunity and checkpoint immunotherapy outcome. It emphasizes the need to study the tumor-associated microbiome in addition to the gut microbiome and calls for further research to understand the mechanisms involved and develop therapeutic strategies. A better understanding of the tumor microbiome can improve cancer immunotherapy and advance precision medicine for solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Correction
Hematology
Verena Petzer, Normann Steiner, Olga Angelova-Unterberger, Gabriele Hetzenauer, Kathrin Philipp-Abbrederis, Ella Willenbacher, Clemens Feistritzer, Wolfgang Willenbacher, Jakob Rudzki, Reinhard Stauder, Florian Kocher, Andreas Seeber, Andreas Pircher, Piotr Tymoszuk, Christian Isara, Alexander Egger, Vilmos Fux, Markus Anliker, Eberhard Gunsilius, David Nachbaur, Stefan Schmidt, Dominik Wolf
Letter
Hematology
Verena Petzer, Normann Steiner, Olga Angelova-Unterberger, Gabriele Hetzenauer, Kathrin Philipp-Abbrederis, Ella Willenbacher, Clemens Feistritzer, Wolfgang Willenbacher, Jakob Rudzki, Reinhard Stauder, Florian Kocher, Andreas Seeber, Andreas Pircher, Piotr Tymoszuk, Christian Isara, Alexander Egger, Vilmos Fux, Markus Anliker, Eberhard Gunsilius, David Nachbaur, Stefan Schmidt, Dominik Wolf
Review
Oncology
Isabel Heidegger, Claudia Kesch, Alexander Kretschmer, Igor Tsaur, Francesco Ceci, Massimo Valerio, Derya Tilki, Giancarlo Marra, Felix Preisser, Christian D. Fankhauser, Fabio Zattoni, Peter Chiu, Ignacio Puche-Sanz, Jonathan Olivier, Roderik C. N. van den Bergh, Veeru Kasivisvanathan, Andreas Pircher, Irene Virgolini, Giorgio Gandaglia
Summary: This narrative review article summarizes recent studies investigating predictive and prognostic clinical, imaging-based, and molecular biomarkers to select the most suitable prostate cancer patients for 177Lu-PSMA-617 radioligand therapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Josia Fauser, Stefan Kock, Eberhard Gunsilius, Andreas Chott, Andreas Peer, Adelheid Ditlbacher, Gernot Fritsche, Michael Joannidis, Dominik Wolf, Andreas Pircher
Summary: HLH is a life-threatening disease characterized by dysregulated immune response. Early diagnosis and treatment are crucial. EBV can trigger HLH, highlighting the importance of early treatment.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
(2021)
Letter
Medicine, General & Internal
Nobuyuki Horita, Nobuhiko Fukuda, Takeshi Kaneko
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Andreas Pircher, Isabel Heidegger, Dominik Wolf
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Oncology
Lena Horvath, Andreas Pircher
Summary: This article summarizes the key highlights of the virtual ASCO 2020 meeting regarding non-small cell lung cancer (NSCLC), covering advancements in both early and advanced-stage NSCLC treatment. It emphasizes the efficacy of targeted therapies in early stage NSCLC and the importance of immunotherapy in advanced-stage disease.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Maruf Hasan, Henry Reyer, Michael Oster, Nares Trakooljul, Siriluck Ponsuksilli, Elizabeth Magowan, Dagmar -Christiane Fischer, Klaus Wimmers
Summary: UVB exposure can increase the supply of vitamin D in pig husbandry and does not affect the growth performance of the pigs. After exposure, there are changes in gene expression in the liver, with the pathways for vitamin D synthesis being preferentially initiated.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2024)
Article
Biochemistry & Molecular Biology
Zhen Wang, Shu-ying Yi, Yuan-ying Zhang, Yu-di Wang, Han-lin Chen, Yi-jie Guo, Xin-ming Wei, Du-xiao Yang
Summary: Vitamin D can reverse S1P-induced cell death and alleviate EAE symptoms by regulating S1P levels and related signaling pathways.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2024)
Correction
Biochemistry & Molecular Biology
Haixiao Chen, Xing Ji, Xinhua Hu, Lihua Chen, Haiyan Lv, Chengyun Xu, Dun Hong, Ximei Wu
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2024)
